Biocon Limited has signed a commercialization agreement with Juno Pharmaceuticals in Canada to market the Indian firm’s “vertically integrated, complex formulation” of liraglutide, a drug-device combination for the treatment and management of type 2 diabetes and obesity.
Under the terms of this deal, Biocon will be responsible for obtaining regulatory approval for liraglutide in Canada, as well as for manufacturing
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?